RyzeRx Review

What RyzeRx charges

RyzeRx does not publish a price today.

RyzeRx also sells 3 compounds this site boards without publishing a price for them: BPC-157 (board ranks no provider), Sermorelin and NAD+.

A floor for a category is not a price for a compound

Its homepage card for peptides names three tracked compounds and adds the words and more, then gives one starting figure for the lot.

Whichever of those three a reader is shopping for, that figure may or may not be theirs, and the page does not say.

So nothing is filed. A category floor recorded as a compound price would put the cheapest item's number on the dearest item's board.

The weight-loss figures name a class, not a drug

Its banner and its weight-loss card price GLP-1 medications, which is a class of drugs rather than one.

Two different figures appear for that class in two places on the same page.

Neither is filed against semaglutide or tirzepatide, because neither is scoped to either.

The fifty is a statistic, not a coverage statement

A number reading fifty sits in a strip of marketing statistics beside a patient count, a provider count and an average rating.

No sentence anywhere on the pages read says the service reaches all fifty states.

So no fifty-state claim is credited here and no state list is recorded. A number in a statistics strip is not an answer to the coverage question.

What it does say

It names the three peptides its category covers rather than describing them generically.

It says its medicines come from United States licensed pharmacies, without naming one, and lists third-party testing among its features without publishing a document.

It publishes its site in English and Spanish from the same navigation, and offers a free consultation before any commitment.

How we verified this

• Read each pricing card and confirmed the peptide figure covers three named compounds and more, then declined to file it against any of them.
• Confirmed both weight-loss figures are attached to a drug class rather than a named drug, and filed neither.
• Read the fifty in its own context — a strip of marketing statistics — and credited no coverage claim from it.
• Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
• Screened the brand against the live federal warning-letter table, filtering locally because the table's own search parameter returns every record whatever is typed into it, with a positive and a nonsense control in the same run.